Email this article The improved form perindopril in treatment of arterial hypertension in various clinical situations (PREMIA)
- Authors: Mychka V.B.1, Zhernakova Y.V1, Chazova I.E.1
-
Affiliations:
- Issue: Vol 6, No 4 (2009)
- Pages: 50-53
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33090
- DOI: https://doi.org/10.26442/SG33090
- ID: 33090
Cite item
Full Text
Abstract
The treatment of ACE inhibitors reduce risk of cardiovascular morbidity and mortality. The patients with grade 1-2 hypertension (n=2060) and at least one additional risk factors, subclinical organ damage, established CV or renal disease, diabetes mellitus or metabolic syndrome are recruited in this clinical study. The article presented of study design.
Keywords
References
- Оганов Р.Г. Эпидемиология артериальной гипертонии. Кардиологический вестник. Бюллетень Российского кардиологического научно-производственного комплекса. Cons. Med. 2007; 2.
- Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med 2003; 253: 472-80.
- World Health Organization - International Society of Hypertension. Guidelines for the Management of Hypertension. Hypertension 1999; 17 (2): 151-83.
- European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.
- The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluated telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with Cardiovascular Disease. Am Heart J 2004; 148: 52-61.
- Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008.
- The European trial on Reduction of cardiacevents with Perindopril in patients with stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
- Ferrari R. PREAMI: Perindopril and Remodeling in Elderly with Acute Myocardial Infarction. Medscape coverage of: European Society of Cardiology 2005 Congress. Available at: www.medscape.com.
- Neal B, MacMahon S. PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee. J Hypertens 1995; 13: 1869-73.
- Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with in antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendoflumetihazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
- Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). Кардиоваск. тер. и профилак. 2008; 6 (Прил. 2).
Supplementary files
